Skip to main content
. Author manuscript; available in PMC: 2021 Jul 15.
Published in final edited form as: Cancer. 2020 May 8;126(14):3360–3371. doi: 10.1002/cncr.32954

Figure 1.

Figure 1.

Effect of napabucasin (BBI 608) on proliferation, and survival (A). The Br-dU assay shows that the napabucasin (BBI 608) treatment significantly decreases the CRC cell line proliferation in a dose dependent pattern. (B). Clonogenic evaluations indicate that the napabucasin or 5-FU combination with radiation (IR) treatment significantly decrease CRC cell line survival in a dose dependent (0GY to 6GY) pattern. (Results are showed as mean ± SD (***p<0.0001; NS, non-significant).